US


NAFTA deal close, but obstacles remain
US and Canada officials continue to meet but there are three key issues to resolve: dairy, intellectual property, dispute settlement.
EU says it is willing to scrap car tariffs in US trade deal
Malmström insists discussions are not about ‘restarting TTIP’ but aiming for ‘a more limited trade agreement.’
Nafta betrayal points to bleak future for US-Canada relationship
Canadians feel stabbed in the back by Mexico after it agreed a separate trade deal with Trump.
Trump’s trade deal with Mexico gives workers more rights than NAFTA. But there’s a catch
When NAFTA was signed, it included labor protections for workers in all three countries. But labor complaints filed through the NAFTA labor dispute process have led nowhere.
Now Carlyle turns to ICSID over $400 million SAMIR claim
Already faced with an arbitration case at ICSID brought by the company's former owner, Morocco now faces another started on August 22 by giant US asset management group Carlyle.
Joint release by USTR Robert Lighthizer and Kenyan Cabinet Secretary for Industry, Trade and Cooperatives, Peter Munya
United States Trade Representative and Kenyan Cabinet Secretary for Industry, Trade and Cooperatives announced the establishment of a US-Kenya Trade and Investment Working Group to explore ways to deepen the trade and investment ties between the two countries.
US plans bilateral free trade agreements with African countries
The US is looking for African countries that would be interested in having bilateral free trade agreements with.
Statement on NAFTA’s “Kafkaesque” turn
Not only the negotiations have not been finalized, and without Canada, but the texts remain hidden from the public.
New NAFTA could include tough intellectual property laws that Canada fought against in TPP
The new trade deal reached between the US and Mexico contains a myriad of rules and tariffs, and among them include tougher rules on copyright and intellectual property.
Biologic drugs would get 10 years of data protection under revised US-Mexico trade deal
The 10-year span is more than what had existed before but the biopharma industry has long argued for the same 12-year exclusivity that exists for biologics within the US market.